Gregory I Vladimer
Overview
Explore the profile of Gregory I Vladimer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
2121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sousa B, de Almeida C, Barahona A, Lopes R, Martins-Logrado A, Cavaco M, et al.
ACS Pharmacol Transl Sci
. 2022 Nov;
5(11):1156-1168.
PMID: 36407952
Bruton's tyrosine kinase (BTK) is a member of the TEC-family kinases and crucial for the proliferation and differentiation of B-cells. We evaluated the therapeutic potential of a covalent inhibitor (JS25)...
2.
Meszaros N, Lind K, Sehlke R, Vilagos B, Krall N, Vladimer G, et al.
Br J Haematol
. 2022 Nov;
200(3):e32-e36.
PMID: 36366863
No abstract available.
3.
Heinemann T, Kornauth C, Severin Y, Vladimer G, Pemovska T, Hadzijusufovic E, et al.
Blood Cancer Discov
. 2022 Sep;
3(6):502-515.
PMID: 36125297
Significance: We have recently demonstrated that image-based drug screening in patient samples identifies effective treatment options for patients with advanced blood cancers. Here we show that using deep learning to...
4.
Kornauth C, Pemovska T, Vladimer G, Bayer G, Bergmann M, Eder S, et al.
Cancer Discov
. 2021 Oct;
12(2):372-387.
PMID: 34635570
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment...
5.
Krall N, Superti-Furga G, Vladimer G
Curr Opin Chem Biol
. 2020 Feb;
56:72-78.
PMID: 32086157
Anticancer drug discovery and development using conventional cell line and animal models has traditionally had a low overall success rate. Despite yielding game-changing new therapeutics, 10-20 new molecules have to...
6.
Valent P, Orazi A, Savona M, Patnaik M, Onida F, van de Loosdrecht A, et al.
Haematologica
. 2019 May;
104(10):1935-1949.
PMID: 31048353
Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm characterized by dysplasia, abnormal production and accumulation of monocytic cells and an elevated risk of transforming into acute leukemia. Over the past...
7.
Schmidl C, Vladimer G, Rendeiro A, Schnabl S, Krausgruber T, Taubert C, et al.
Nat Chem Biol
. 2019 Jan;
15(3):232-240.
PMID: 30692684
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has substantially improved therapeutic options for chronic lymphocytic leukemia (CLL). Although ibrutinib is not curative, it has a profound effect on CLL cells...
8.
Brandstetter B, Dalwigk K, Platzer A, Niederreiter B, Kartnig F, Fischer A, et al.
Lab Invest
. 2019 Jan;
99(5):648-658.
PMID: 30679758
Fibroblast-like synoviocytes (FLS) are major contributors to joint inflammation in rheumatoid arthritis (RA). Forkhead box O 3 (FOXO3) perturbations in immune cells are increasingly linked to RA pathogenesis. Here, we...
9.
Bigenzahn J, Collu G, Kartnig F, Pieraks M, Vladimer G, Heinz L, et al.
Science
. 2018 Nov;
362(6419):1171-1177.
PMID: 30442766
In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 () gene led to...
10.
Snijder B, Vladimer G, Krall N, Miura K, Schmolke A, Kornauth C, et al.
Lancet Haematol
. 2017 Nov;
4(12):e595-e606.
PMID: 29153976
Background: Patients with refractory or relapsed haematological malignancies have few treatment options and short survival times. Identification of effective therapies with genomic-based precision medicine is hampered by intratumour heterogeneity and...